Search company, investor...

Oncoscope

oncoscope.com

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$4.45M

About Oncoscope

Oncoscope was founded in June 2006 to develop clinical applications of discoveries in the field of optical imaging pioneered by Dr. Adam Wax at the Department of Biomedical Engineering at Duke University. This technology, known as Angle-resolved Low Coherence Interferometry (a/LCI) arose from work supported by grants from the National Cancer Institute, the National Science Foundation, and the Wallace H. Coulter Foundation.

Headquarters Location

318 Blackwell Street Suite 240

Durham, North Carolina, 27701,

United States

919-251-8030

Missing: Oncoscope's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oncoscope's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oncoscope

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oncoscope is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

8,592 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,578 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

H

Health IT

7,901 items

Latest Oncoscope News

Applied Materials detects Oncoscope exit

Feb 26, 2016

26 February 2016 Applied Materials detects Oncoscope exit SpectraScience has acquired the assets of Applied Materials-backed oncology diagnostics technology developer Oncoscope for an undisclosed sum. Author: Robert Lavine, News Editor Medical device maker SpectraScience has acquired the assets of Oncoscope, a US-based optical imaging system developer backed by industrial manufacturing equipment provider Applied Materials, for an undisclosed amount. This rest of this content is only accessible to Global Corporate Venturing Subscribers This content is only accessible to subscribers. If you are a subscriber,please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Oncoscope Frequently Asked Questions (FAQ)

  • When was Oncoscope founded?

    Oncoscope was founded in 2006.

  • Where is Oncoscope's headquarters?

    Oncoscope's headquarters is located at 318 Blackwell Street, Durham.

  • What is Oncoscope's latest funding round?

    Oncoscope's latest funding round is Acquired.

  • How much did Oncoscope raise?

    Oncoscope raised a total of $4.45M.

  • Who are the investors of Oncoscope?

    Investors of Oncoscope include SpectraScience, Applied Ventures, IDEA Fund Partners, Arcus Ventures and Southeast Techinventures.

  • Who are Oncoscope's competitors?

    Competitors of Oncoscope include Signostics, Oxford BioDynamics, MEC Dynamics, Dexela, Spectral Image and 11 more.

Compare Oncoscope to Competitors

R
Real Imaging

Real Imaging is developing an imaging solution for breast cancer detection which is both accurate and patient-friendly. Real imaging's MIRA technology will increase correct detection rates and decrease the amount of false diagnoses for women of all ages around the globe.

F
Forth Photonics

Forth Photonics is a medical device company that designs, develops, manufactures and markets imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Forth Photonics aims to help medical practitioners to improve patient care by incorporating advanced biophotonics and optical molecular imaging technologies to assist in early detection, diagnosis and monitoring.

D
Diamics

Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.

T
Third Eye Diagnostics

Third Eye Diagnostics is developing the Cerepress, a first-of-its-kind non-invasive intracranial pressure monitor that gathers information from the patient's eye. The technology is based on one issued patent, one pending patent, and two applications in progress on methods and apparatus that correlate ICP with measurements taken from the blood vessels within the eye. The Cerepress measures blood pressure in the eye's central retinal vein (CRV) which highly correlates to intracranial pressure.

Stage I Diagnostics Logo
Stage I Diagnostics

Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.

O
Orison

Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.